Literature DB >> 22313954

Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration.

David Croteau1, Brookie M Best, Scott Letendre, Steven S Rossi, Ronald J Ellis, David B Clifford, Ann C Collier, Benjamin B Gelman, Justin C McArthur, John Allen McCutchan, Susan Morgello, Igor Grant.   

Abstract

To measure maraviroc total cerebrospinal fluid (CSF) concentrations and compare them with total and unbound plasma concentrations. Total maraviroc was measured by reverse-phase high-performance liquid chromatography with tandem mass spectrometry, whereas ultrafiltration was used for unbound maraviroc. Maraviroc was detected in all nine CSF/plasma pairs with a median CSF total concentration of 2.4 ng/ml. CSF concentrations exceeded the 50% inhibitory concentration of wild-type CC chemokine receptor 5-tropic HIV-1 in all specimens. CSF concentrations are lower than expected based on plasma concentrations and physicochemical characteristics. Unbound maraviroc plasma concentrations may be informative in estimating concentrations in CSF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22313954      PMCID: PMC3454507          DOI: 10.1097/QAD.0b013e328351f627

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

1.  Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

Authors:  Aylin Yilmaz; Victoria Watson; Laura Else; Magnus Gisslèn
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

2.  Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

Authors:  Don K Walker; Samantha Abel; Pierre Comby; Gary J Muirhead; Angus N R Nedderman; Dennis A Smith
Journal:  Drug Metab Dispos       Date:  2005-01-13       Impact factor: 3.922

3.  Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.

Authors:  Marlene Smurzynski; Kunling Wu; Scott Letendre; Kevin Robertson; Ronald J Bosch; David B Clifford; Scott Evans; Ann C Collier; Michael Taylor; Ronald Ellis
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

4.  Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.

Authors:  Juan Manuel Tiraboschi; Jordi Niubo; Jordi Curto; Daniel Podzamczer
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

5.  Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT).

Authors:  D K Walker; S J Bowers; R J Mitchell; M J Potchoiba; C M Schroeder; H F Small
Journal:  Xenobiotica       Date:  2008-10       Impact factor: 1.908

6.  CSF and serum orosomucoid (alpha-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients.

Authors:  Pavel Adam; Ondrej Sobek; Ludek Táborský; Thomas Hildebrand; Olga Tutterová; Petr Zácek
Journal:  Clin Chim Acta       Date:  2003-08       Impact factor: 3.786

7.  Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates.

Authors:  A V Albright; J T Shieh; T Itoh; B Lee; D Pleasure; M J O'Connor; R W Doms; F González-Scarano
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

8.  Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders.

Authors:  Scott L Letendre; J Allen McCutchan; Meredith E Childers; Steven P Woods; Deborah Lazzaretto; Robert K Heaton; Igor Grant; Ronald J Ellis
Journal:  Ann Neurol       Date:  2004-09       Impact factor: 10.422

9.  Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.

Authors:  Christina M Marra; Yu Zhao; David B Clifford; Scott Letendre; Scott Evans; Katherine Henry; Ronald J Ellis; Benigno Rodriguez; Robert W Coombs; Giovanni Schifitto; Justin C McArthur; Kevin Robertson
Journal:  AIDS       Date:  2009-07-17       Impact factor: 4.177

10.  Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma.

Authors:  David W Haas; Benjamin Johnson; Janet Nicotera; Vicki L Bailey; Victoria L Harris; Farideh B Bowles; Stephen Raffanti; Jennifer Schranz; Tyler S Finn; Alfred J Saah; Julie Stone
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more
  11 in total

Review 1.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

Review 2.  CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.

Authors:  Guillaume Martin-Blondel; David Brassat; Jan Bauer; Hans Lassmann; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

3.  Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.

Authors:  Catia Marzolini; Rajith Rajoli; Manuel Battegay; Luigia Elzi; David Back; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

Review 4.  Pharmacologic approaches to HIV-associated neurocognitive disorders.

Authors:  Sean N Avedissian; Shetty Ravi Dyavar; Howard S Fox; Courtney V Fletcher
Journal:  Curr Opin Pharmacol       Date:  2020-10-10       Impact factor: 5.547

Review 5.  HIV-associated neurocognitive disorders: perspective on management strategies.

Authors:  Linda Nabha; Lan Duong; Joseph Timpone
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

Review 6.  Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.

Authors:  Andrea Calcagno; Giovanni Di Perri; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

7.  Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.

Authors:  Eugene L Asahchop; Oussama Meziane; Manmeet K Mamik; Wing F Chan; William G Branton; Lothar Resch; M John Gill; Elie Haddad; Jean V Guimond; Mark A Wainberg; Glen B Baker; Eric A Cohen; Christopher Power
Journal:  Retrovirology       Date:  2017-10-16       Impact factor: 4.602

Review 8.  Harnessing nanostructured systems for improved treatment and prevention of HIV disease.

Authors:  Maya Monroe; Charles Flexner; Honggang Cui
Journal:  Bioeng Transl Med       Date:  2018-07-27

Review 9.  Maraviroc: a review of its use in HIV infection and beyond.

Authors:  Shawna M Woollard; Georgette D Kanmogne
Journal:  Drug Des Devel Ther       Date:  2015-10-01       Impact factor: 4.162

Review 10.  Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system.

Authors:  Maria João Gomes; José das Neves; Bruno Sarmento
Journal:  Int J Nanomedicine       Date:  2014-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.